J&J: new data published on Uptravi

(CercleFinance.com) - An analysis of the first 500 patients enrolled in the SPHERE registry shows that 76% of patients treated with Uptravi (selexipag) for pulmonary arterial hypertension (PAH) maintained (56%) or reduced (20%) their risk of mortality at one year, J&J announced today.


SPHERE (SelexiPag: the usErs dRug rEgistry,) is a registry that uses two methods of observing and describing the clinical characteristics, outcomes, and dosing regimens seen in PAH patients treated with Uptravi.

The results of the SPHERE analysis reinforce the need for physicians to conduct regular comprehensive risk assessments and use available tools such as risk calculators to ensure PAH patients are meeting their treatment goals, said Nick Kim, lead investigator and professor of medicine at the University of California, San Diego.

The findings were published in the April issue of the Journal of Heart and Lung Transplantation (JHLT).


Copyright (c) 2021 CercleFinance.com. All rights reserved.